{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-013984","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.921779+00:00","generated_at":"2026-05-24T10:09:37.969049+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Avalo reports 2024 net loss of $35.1M; cash of $134.5M funds into at least 2027","bullets":["Cash and equivalents $134.5M at Dec 31, 2024 vs $7.4M in 2023; runway into at least 2027.","Net loss $35.1M in 2024 ($7.94 basic EPS) vs $31.5M loss in 2023; diluted EPS -$20.91.","R&D expense $24.4M, up $10.7M, driven by Phase 2 LOTUS trial of AVTX-009 in hidradenitis suppurativa.","Topline data from Phase 2 LOTUS trial expected in 2026; second indication for AVTX-009 planned.","Appointed Jennifer Riley as Chief Strategy Officer effective January 1, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-013984","json":"https://secwatch.observer/filing/0001628280-25-013984.json","markdown":"https://secwatch.observer/filing/0001628280-25-013984.md","text":"https://secwatch.observer/filing/0001628280-25-013984.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828025013984/0001628280-25-013984-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828025013984/avtx-20250320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T10:09:37.969049+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}